The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Abstract excerpt

RAS oncogenes are chief tumorigenic drivers, and their mutation constitutes a universal predictor of poor outcome and treatment resistance. Despite more than 30 years of intensive research since the identification of the first RAS mutation, most attempts to therapeutically target RAS mutants have failed to reach the clinic. In fact, the first mutant RAS inhibitor, Sotorasib, was only approved by the FDA until...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy